Development of new anti-tuberculosis drug candidates

Tohoku Journal of Experimental Medicine

Volumn 221, Issue 2, 2010, Pages 97-106

  Shi, Ruiru ^a   Sugawara, Isamu ^b  

^a Henan Provincial Cancer Hospital   (China)

^b RESEARCH INSTITUTE OF TUBERCULOSIS   (Japan)

Author keywords

Anti tuberculosis drug candidates; M. tuberculosis; Mechanism of action; Multi drug resistance; XDR TB

Indexed keywords

1 (6 BROMO 2 METHOXY 3 QUINOLINYL) 4 DIMETHYLAMINO 2 (1 NAPHTHYL) 1 PHENYL 2 BUTANOL; 2 THYL 5 NITRO 2,3 DIHYDRO[2-1B]IMIDAZO OXAZOLE; 2,3 DIHYDRO 2 METHYL 6 NITRO 2 [4 [4 (4 TRIFLUOROMETHOXYPHENOXY) 1 PIPERIDINYL]PHENOXYMETHYL]IMIDAZO[2,1 B]OXAZOLE; 6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; CGI 17341; DICYCLOHEXYLCARBODIIMIDE; ETHAMBUTOL; GATIFLOXACIN; ISONIAZID; LINEZOLID; LL 3858; MOXIFLOXACIN; N (2 ADAMANTYL) N' GERANYLETHYLENEDIAMINE; NITROIMIDAZOLE DERIVATIVE; PLACEBO; PYRAZINAMIDE; PYRROLE DERIVATIVE; QUINOLONE DERIVATIVE; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ANEMIA; ANTIBACTERIAL ACTIVITY; BACTERIAL STRAIN; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER DISEASE; LONG TERM CARE; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MIXED INFECTION; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NAUSEA; NONHUMAN; OPTIC NERVE DISEASE; PERIPHERAL NEUROPATHY; REVIEW; SINGLE DRUG DOSE; SKIN DISEASE; THROMBOCYTOPENIA; TUBERCULOSIS; UNSPECIFIED SIDE EFFECT;

ANTITUBERCULAR AGENTS; DRUG DISCOVERY; DRUG RESISTANCE, BACTERIAL; HUMANS; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS;

EID: 77952366279     PISSN: 00408727     EISSN: 13493329     Source Type: Journal    
DOI: 10.1620/tjem.221.97     Document Type: Review

References (58)

1. Alcala, L., Ruiz-Serrano, M.J., Peres-Fernandez Turegano, C., Carcia De Viedma, D., Diaz-Infantes, M., Marin-Arriaza, M. & Bouza, E. (2003) In vitro activities of linezolid against clinical isolates of Mycobacterium tuberculosis that are susceptible or resistant to irst-line antituberculous drugs. Antimicrob. Agents Chemother., 47, 416-417.
2. Andries, K., Verhasselt, P., Guillemont, J., Gohlmann, H.W., Neefs, J.M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., Williams, P., de Chaffoy, D., Huitric, E., Hoffner, S., Cambau, E., Truffot-Pernot, C., Lounis, N. & Jarlier, V. (2005) A diarylquinoline drug active on ATP synthase of Mycobacterium tuberculosis. Science, 307, 223-227.
3. Arora, S. (2004) Eradication of Mycobacterium tuberculosis infection in 2 months with LL3858: a preclinical study. Int. J. Tuberc. Lung Dis., 8 (Suppl.1): S29. Ashtekar, D.R., Costa-Perira, R., Nagrajan, K., Vishvanathan, N., Bhatt, A.D. & Rittel, W. (1993) In vitro and in vivo activities of the nitroimidazole CGI17341 against Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 37, 183-186.
4. Chen, P., Gearhart, J., Protopopova, M., Einck, L. & Nacy, C.A. (2006) Synergistic interactions of SQ109, a new ethylene diamine, with front-line antitubercular drugs in vitro. J. Antimicrob. Chemother., 58, 332-337.
5. Diacon, A.H., Pym, A., Grobusch, M., Patientia, R., Rustomjee, R., Page-Shipp, L., Pistorius, C., Krause, R., Bogoshi, M., Churchyard, G., Venter, A., Allen, J., Palomino, J.C., De Marez, T., van Heeswijk, R.P., Lounis, N., Meyvisch, P., Verbeeck, J., Parys, W., de Beule, K., Andries, K. & McNeeley, D.F. (2009) The diarylquinoline TMC207 for multidrugresistant tuberculosis. N. Engl. J. Med., 360, 2397-2405.
6. Fortun, J., Martin-Davila, P., Navas, E., Peres-Elias, M.J., Cobo, J., Tato, M., de la Pedrosa, E.G., Gomez-mampaso, E. & Moreno, S. (2005) Linezolid for the treatment of multidrugresistant tuberculosis. J. Antimicrob. Chemother., 56, 180-185.
7. Gelber, R., Andries, K., Paredes, R.M., Andaya, C.E. & Burgos J. (2009) The diarylquinoline R207910 is bactericidal against Mycobacterium leprae in mice at low dose and administered intermittently. Antimicrob. Agents Chemother., 53, 3989-3991.
8. Ginsberg, A.M. (2008) Emerging drugs for active tuberculosis. Semin. Respir. Crit. Care Med., 29, 552-559.
9. Ginsberg, A.M., Laurenzi, M.W., Rouse, D.J., Whitney, K.D. & Spigelman, M.K. (2009) Safety, tolerability and pharmacokinetics of PA-824 in healthy subjects. Antimicrob. Agents Chemother., 53, 3720-3725.
10. Ginsberg, A.M., Laurenzi, M.W., Rouse, D., Whitney, K.D. & Spigelman, M.K. (2009) Assessment of the effects of the nitroimidazo-oxazine, PA-824, on renal function in healthy subjects. Antimicrob. Agents Chemother., 53, 3726-3733.
11. Global Alliance for TB Drug Development (2009) TB drug portfolio: PA-824. TB alliance http://www.tballiance.org/new/portfolio www.tballiance.org/new/portfolio).
12. Haagsma, A.C., Abdillahi-Ibrahim, R., Wagner, M.J., Krab, K., Vergauwen, K., Gullemont, J., Andries, K., Lill, H., Koul, A. &Bald, D. (2009) Selectivity of TMC207 towards mycobacterial ATP synthase compared with that towards the eukaryotichomologue. Antimicrob. Agents Chemother., 3, 1290-1292.
13. Hillemann, D., Rusch-Gerdes, S. & Richter, E. (2008) In vitroselected linezolid-resistant Mycobacterium tuberculosis mutants. Antimicrob. Agents Chemother., 52, 800-801.
14. Hu, Y., Coates, A.R.M. & Mitchison, D.A. (2003) Sterilizing activities of luoroquinolones against rifampin-tolerant populations of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 47, 653-657.
15. Hu, Y., Coats, A.R. & Mitchison, D.A. (2008) Comparison of the sterilizing activities of the nitroimidazopyran PA-824 and moxiloxacin against persisting Mycobacterium tuberculosis. Int. J. Tuberc. Lung Dis., 12, 69-73.
16. Huitric, E., Verhasselt, P., Koul, A., Andries, K., Hoffner, S. & Andersson, D.I. (2010) Rates and mechanisms of resistance development in Mycobacterium tuberculosis to a novel diarylquinoline ATP synthase inhibitor. Antimicrob. Agents Chemother., 54, 1022-1028.
17. Ibrahim, M., Andries, K., Lounis, N., Jarlier, V. & Veziris, N. (2007) Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob. Agents Chemother., 51, 1011-1015.
18. Ibrahim, M., Truffot-Pernot, C., Andries, K., Jarlier, V. & Veziris, N. (2009) Sterilizing activity of R207910 (TMC207)-containing regimens in the murine model of tuberculosis. Am. J. Respir. Crit. Care Med., 180, 553-557.
19. Jia, L., Tomaszewski, J.E., Hanrahan, C., Coward, L., Noker, P., Gorman, G., Nikonenko, B. & Protopopova, M. (2005) Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Br. J. Pharmacol., 144, 80-87.
20. Kaiser Family Foundation. Open Forum on Key Issues in TB Drug Development, London, United Kingdom. HYPERLINK "http://www.kaisernetwork.org/health_cast. Accessed 22 Nov 2009"http://www.kaisernetwork.org/health_cast. Accessed 22 Nov 2009.
21. Kubendiran, G., Paramasivan, C.N., Sulochana, S. &Mitchison, D.A. (2006) Moxiloxacin and gatiloxacin in an acid model of persistent Mycobacterium tuberculosis. J. Chemother., 18, 617-623.
22. Lenaerts, A.J., Gruppo, V., Marietta, K.S., Johnson, C.M., Driscoll, D.K., Tompkins, N.M., Rose, J.D., Reynolds, R.C. & Orme, I.M. (2005) Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models. Antimicrob. Agents Chemother., 49, 2294-2301.
23. Lounis, N., Gevers, T., Van Den Berg, J. & Andries, K. (2008) Impact of the interaction of R207910 with rifampin on the treatment of tuberculosis studied in the mouse model. Antimicrob. Agents Chemother., 52, 3568-3572.
24. Manjunatha, U.H., Boshoff, H., Dowd, C.S., Zhang, L., Albert, T.J., Norton, J.E., Daniels, L., Dick, T., Pang, S.S. & Barry, C.E. 3rd. (2006a) Identiication of a nitroimidazo-oxazine-speciic protein involved in PA-824 resistance in Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA, 103, 431-436.
25. Manjunatha, U.H., Lahiri, R., Randhawa, B., Dowd, C.S., Krahenbuhl, J.L. & Barry, C.E. 3rd. (2006b) Mycobacterium leprae is naturally resistant to PA-824. Antimicrob. Agents Chemother., 50, 3350-3354.
26. Matsumoto, M., Hashizume, H., Tomoshige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y. & Komatsu, M. (2006) OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice. Plos Med., 3:e466. Meng, Q., Luo, H., Liu, Y., Li, W., Zhang, W. & Yao, Q. (2009) Synthesis and evaluation of carbamate prodrugs of SQ109 as antituberculosis agents. Bioorg. Med. Chem. Lett., 19, 2808-2810.
27. Nijland, H.M., Ruslami, R., Suroto, A.J., Burger, D.M., Alisjahbana, B., van Crevel, R. & Aarnoutse, R.E. (2007) Rifampicin reduces plasma concentrations of moxiloxacin in patients with tuberculosis. Clin. Infect. Dis., 45, 1001-1007.
28. Nikonenko, B.V., Protopopova, M., Samala, R., Einck, L. & Nacy, C.A. (2007) Drug therapy of experimental tuberculosis (TB): improved outcome by combining SQ109, a new diamine antibiotic, with existing TB drugs. Antimicrob. Agents Chemother., 51, 1563-1565.
29. Nuermberger, E. & Mitchison, DA. (2009) Once-weekly treatment of tuberculosis with the diarylquinoline R207910; a real possibility. Am. J. Respir. Crit. Care Med., 179, 2-3.
30. Nuermberger, E., Rosenthal, I., Tyagi, S., Williams, K.N., Almeida, D., Peloquin, C.A., Bishai, W.R. & Grosset, J.H. (2006) Combination chemotherapy with the nitroimidazopyran PA-824 and irst-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother., 50, 2621-2625.
31. Nuermberger, E., Tyagi, S., Tasneen, R., Williams, K.N., Almeida, D., Rosenthal, I. & Grosset, J.H. (2008) Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxiloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob. Agents Chemother., 52, 1522-1524.
32. Nuermberger, E., Tyagi, S., William, K.N., Rosenthal, I., Bishai, W.R. & Grosset, J.H. (2005) Rifapentine, moxiloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am. J. Respir. Crit. Care Med., 172, 1452-1456.
33. Paramasivan, C.N., Sulochana, S., Kubendiran, G., Venkatesan, P. & Mitchison, D.A. (2005) Bactericidal action of gatiloxacin, rifampin, and isoniazid on logarithmic- and stationary-phase cultures of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 49, 627-631.
34. Pletz, M.W., De Roux, A., Roth, A., Neumann, K.H., Mauch, H. & Lode, H. (2004) Early bactericidal activity of moxiloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob. Agents Chemother., 48, 780-782.
35. Protopopova, M., Bogatcheva, E., Nikonenko, B., Hundert, S., Einck, L. & Nacy, C.A. (2007) In search of new cures for tuberculosis. Med. Chem., 3, 301-316.
36. Protopopova, M., Hanrahan, C., Nikonenko, B., Samala, R., Chen, P., Gearhart, J., Einck, L. & Nacy, C.A. (2005) Identiication of a new antitubercular drug candidate, SQ109, from a corabinatorial library of 1,2-ethylenediamines. J. Antimicrob. Chemother., 56, 968-974.
37. Richter, E., Rusch-Gerdes, S. & Hillemann, D. (2007) First linezolidresistant clinical isolates of Mycobacterium tuberculosis. Antimicrob. Agents Chemother., 51, 1534-1536.
38. Rodriguez, J.C., RuiZ, M., Lopez, M. & Royo, G. (2002) In vitro activity of moxiloxacin, levoloxacin, gatiloxacin and linezolid against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents, 20, 464-467.
39. Rosenthal, I.M., Williams, K., Tyagi, S., Peloquin, C.A., Vernon, A., Bishai, W.R., Grosset, J.H. & Nuermberger, E.L. (2006) Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am. J. Respir. Crit. Care Med., 174, 94-101.
40. Rustomjee, R., Diacon, A., Allen, J., Venter, A., Reddy, C., Patientia, R.F., Mthiyane, T.C., De Marez, T., van Heeswijk, R., Kerstens, R., Koul, A., De Beule, K., Donald, P.R. & McNeeley, D.F. (2008a) Early bactericidal activity and pharmacokinetics of the investigational diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob. Agents Chemother., 52, 2831-2835.
41. Rustomjee, R., Lienhardt, C., Kanyok, T., Davies, G.R., Levin, J., Mthiyane, T., Reddy, C., Sturm, A.W., Sirgel, F.A., Allen, J., Coleman, D.J., Fourie, B. & Mitchison, D.A. (2008b) A phase II study of the sterilizing activities of oloxacin, gatiloxacin and moxiloxacin in pulmonary tuberculosis. Int. J. Tuberc. Lung Dis., 12, 128-138.
42. Sasaki, H., Haraguchi, Y., Itotani, M., Kuroda, H., Hashizume, H., Tomishige, T., Kawasaki, M., Matsumoto, M., Komatsu, M. & Tsubouchi, H. (2006) Synthesis and antituberculosis activity[2,1-b] oxazoles. J. Med. Chem., 49, 7854-7860.
43. Shandil, R.K., Jayaram, R., Kaur, P., Gaonkar, S., Suresh, B.L., Mahesh, B.N., Jayashree, R., Nandi, V., Bharath, S. & Balasubramanian, V. (2007) Moxiloxacin, oloxacin, sparloxacin, and ciproloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo eficacy. Antimicrob. Agents Chemother., 51, 576-582.
44. Shi, R., Itagaki, N. & Sugawara, I. (2007) Overview of anti-tuberculosis drugs and their resistance mechanisms. Mini. Rev. Med. Chem., 7, 1177-1185.
45. Shindikar, A.V. & Viswanathan, C.L. (2005) Novel luoroquinolones: design, synthesis, and in vivo activity in mice against Mycobacterium tuberculosis H37Rv. Bioorg. Med. Chem. Lett., 15, 1803-1806.
46. Singh, R., Manjunatha, U., Boshoff, H.I.M., Ha, Y.H., Niyomrattanakit, P., Ledwidge, R., Dowd, C.S., Lee, I.Y., Kim, P., Zhang, L., Kang, S., Keller, T.H., Jiricek, J. & Barry, C.E. 3rd. (2008) PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release. Science, 322, 1392-1395.
47. Stover, C.K., Warrener, P., VanDevanter, D.R., Sherman, D.R., Arain, T.M., Langhorne, M.H., Anderson, S.W., Towell, J.A., Yuan, Y., McMurray, D.N., Kreiswirth, B.N., Barry, C.E. & Baker, W.R. (2000) A small molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature, 405, 962-966.
48. Sung, J.C., Garcia-Contreras, L., Verberkmoes, J.L., Peloquin, C.A., Elbert, K.J., Hickey, A.J. & Edwards, D.A. (2009) Dry powder nitroimidazopyran antibiotic PA-824 aerosol for inhalation. Antimicrob. Agents Chemother., 53, 1338-1343.
49. Tyagi, S., Nuermberger, E., Yoshimatsu, T., Williams, K., Rosenthal, I., Lounis, N., Bishai, W. & Grosset, J. (2005) Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis. Antimicrob. Agents Chemother., 49, 2289-2293.
50. Umubyeyi, A.N., Rigouts, L., Shamputa, I.C., Fissette, K., Elkrim, Y., de Rijk, P.W., Struelens, M.J. & Portaels, F. (2007) Limited luoroquinolone resistance among Mycobacterium tuberculosis isolates from Rwanda: results of a national surgery. J. Antimicrob. Chemother., 59, 1031-1033.
51. Veziris, N., Ibrahim, M., Lounis, N., Chauffour, A., Truffot-Pernot, C., Andries, K. & Jarlier, V. (2009) A once-weekly R207910- containing regimen exceeds activity of the standard daily regimen in murine tuberculosis. Am. J. Respir. Crit. Care Med., 179, 75-79.
52. Van den Boogaard, J., Kibiki, G.S., Kisanga, E.R., Boeree, M.J. & Aarnoutse, R.E. (2009) New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development. Antimicrob. Agents Chemother., 53, 849-862.
53. Von der Lippe B., Sandven, P. & Brubakk, O. (2006) Eficacy and safety of linezolid in multidrug resistant tuberculosis (MDRTB)- a report of ten cases. J. Infect., 52, 92-96.
54. Wright, A., Zignol, M., Van Deun, A., Falzon, D., Gerdes, S.R., Feldman, K., Hoffner, S., Drobniewski, F., Barrera, L., van Soolingen, D., Boulabhal F., Paramasivan, C.N., Kam, K.M., Mitarai, S., Nunn, P. & Raviglione, M. (2009) Epidemiology of antituberculosis drug resistance 2002-07: an update analysis of the Global Project on Anti-tuberculosis Drug Resistance Surveillance. Lancet, 373, 1861-1873.
55. Yoshimatsu, T.E., Nuermberger, E., Tyagi, S., Chaisson, R., Bishai, W. & Grosset, J. (2002) Bactericidal activity of increasing daily and weekly doses of moxiloxation in murine tuberculosis. Antimicrob. Agents Chemother., 46, 1875-1879.
56. Zhang, Y. (2004) Persistent and dormant tubercle bacilli and latent tuberculosis. Front. Biosci., 9, 1136-1156.
57. Zhang, Y., Post-Martens, K. & Denkin, S. (2006) New drug candidates and therapeutic targets for tuberculosis therapy. Drug Discovery Today, 11, 21-27.
58. Zhang, Y., Wade, M.M., Scorpio, A., Zhang, H. & Sun, Z. (2003) Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetic by pyrazinoic acid. J. Antimicrob. Chemother., 52, 790-795.